Memphis Pharmaceuticals results, Q3 2024
Net profit, assets, equity and cash flow for Q3 2024, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit83.48 millionEGP · +1012.8% vs the same period a year earlier
Total assets1.13 billionEGP · +71.8% vs the same period a year earlier
Shareholders' equity67.73 millionEGP · +16.9% vs the same period a year earlier
Operating cash flow-92.61 millionEGP · −63.3% vs the same period a year earlier
In short
- Memphis Pharmaceuticals's net profit for Q3 2024 was about 83.48 million EGP, up +1012.8% from 7.5 million EGP in Q3 2023.
- Total assets at the end of Q3 2024 were about 1.13 billion EGP, and shareholders' equity about 67.73 million EGP.
- Operating cash flow for Q3 2024 was negative at 92.61 million EGP.
Key lines against the same period a year earlier
This periodQ3 2023Change
Net profit83.48 million7.5 million+1012.8%
Gross profit78.75 million36.06 million+118.4%
Total assets1.13 billion656 million+71.8%
Total liabilities1.06 billion598 million+77.1%
Shareholders' equity67.73 million57.94 million+16.9%
Total liabilities and equity1.13 billion656 million+71.8%
Operating cash flow-92.61 million-56.73 million−63.3%
Investing cash flow5.58 million-401 thousand+1492.3%
Financing cash flow64.91 million0—
Net change in cash-22.12 million-57.13 million+61.3%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy